Quoted By:
bavarian nordic bros
>Bavarian Nordic A/S today announced that it had received a new order valued at USD 156.8 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to manufacture additional bulk product for JYNNEOS® (MVA-BN®, IMVAMUNE®, IMVANEX®), the company’s smallpox/mpox vaccine.